Stada Health Report 2021

According to the third Stada Health Report, a representative survey of 30,000 participants in 15 European countries, 29% have suffered from increased levels of anxiety during the pandemic, while 25% are troubled by stress and inner restlessness and 15% have reported sleep disturbances. Some 52% of respondents are more affected by the lack of personal contact with family & friends than fear of Covid infection (42%), while almost 1 in 3 worries about the financial and work-related repercussions.

However, 70% of Europeans have been willing to invest more in their own health. For 73%, their doctor is the first point of call for all health-related issues, with pharmacists and scientists also highly trusted (60% each). Despite a 14 percentage-point increase in people purchasing medication online, 43% stay loyal to community pharmacies, 13% of which specifically single out their local branch. Europeans care more about brand names and what is associated with them (38%) rather than sustainable & environmentally-friendly packaging (25%) or whether a product was made in Europe (20%).

In the report, Stada asks the question, “With an increased interest in and an aspiration to healthy living, how did people in Europe procure information on these topics? The short answer is: The internet. 54% of Europeans have increased their online searches for health-related information compared to previous years.” However, this spike in online health searches and literacy has not automatically translated into European consumers looking to bypass their pharmacist when acquiring medication, or information about it. According to Stada’s survey, only 14% of Europeans have ordered more OTC medicines via online pharmacies post-pandemic, and 43% flat out refuse to order them online at all. Despite the ever increasing number of e-Commerce platforms and other channels for obtaining medicines online, community pharmacies are still Europe’s first choice for OTCs.

Nicholas Hall’s Touchpoints: The Stada report quoted above is further evidence that increased levels of stress and anxiety, and disrupted sleep, are by-products of Covid. Insomnia was already considered a pandemic in the Western world by the World Health Organization; and sleep, stress and mood have joined immunity and disinfection as categories with rocketing sales in the past two years … The theme continues in the latest Gallup survey, which notes the high incidence of “worry, stress, anger and sadness among employees worldwide”. It seems that substantial numbers of office workers are refusing to go back to work in the traditional way and are insisting on continuing to work from home … This localisation of labour will almost certainly change our concept of shopping and could benefit independent neighbourhood pharmacies, giving a whole new meaning to the concept of Pharmacy Point-of-Care. It’s too soon to draw definite conclusions, but consumer healthcare companies would do well to re-examine their sales force objectives. One of the most successful modules of the CHC Training Academy is “Winning in Pharmacy”, and I can see this being even more popular as we come out of the Covid lockdown.

To find out more about Winning in Pharmacy, or the offerings from The CHC Training Academy, please contact maricar.montero@NicholasHall.com. The CHC Training Academy can also work with you to develop your own in-house customised training programmes according to your specific strategic needs.

AESGP 57th Annual Meeting Review

From CHC Insight Europe Editor, Sarah Carter, who reports that the AESGP sees a brilliant future for self-care, but that the industry must continue to adapt.

Focusing on self-care in times of the pandemic and beyond, the 57th AESGP Annual Meeting discussed opportunities, challenges and lessons learnt. While the pandemic has caused significant disruption and altered behaviours, priorities and shopping habits, it has driven a surge in interest in self-care, with consumers increasingly looking to stay well and prevent illness. Birgit Schuhbauer, who has just been re-elected as AESGP President for the next two years, stated that the CHC industry has a “brilliant future ahead of us”.

The CHC industry has had to adapt to this changing landscape, although a number of speakers stressed that it must do so at a quicker pace as technology and evolving consumer demands continue to disrupt the traditional self-care model. AESGP Director General Jurate Svarcaite concluded that there is no going back to the old model, stressing that the “new normal” requires collaboration and partnership.

Speakers also touched upon the infodemic and the increasing consumer appetite for instant information, which European Medicines Agency Executive Director Emer Cooke said was difficult to manage when you try to have a “sound scientific basis for what you communicate”. However, the worrying spread of misinformation and disinformation means that increased and better communication is vital.

The Annual Meeting coincided with the long-awaited implementation of the new EU Medical Device Regulation; participants shared their excitement and optimism at the development and celebrated how much work had been done, but were keen to stress there remains a way to go, particularly in terms of harmonisation across Europe and the capacity of notified bodies.

There is still time to register for our free webinar on 30 June discussing the topline conclusions from our upcoming report on Eye Health! With no purchase necessary, you can register directly for the webinar here. For more information, please contact melissa.lee@NicholasHall.com.

Rx-to-OTC switch drivers

Allergy and sexual health are two areas of the global CHC market that continue to expand in sales thanks to Rx to non-prescription switch activity in various markets. In Japan, the Ministry of Health, Labour & Welfare’s Evaluation (MHLW) Review Conference will discuss the potential Rx-to-OTC switch of emergency hormonal contraceptives at a meeting this week.

According to CHC Insight Asia-Pacific Senior Editor, Nicola Allan: “In June 2019, an MHLW steering committee permitted pharmacists to dispense EHCs during a face-to-face transaction after the consumer has had an online consultation with a doctor. Previously, the patient had to see a doctor face-to-face to obtain a prescription to give to the pharmacist. More than 9,000 pharmacists have undertaken training that allows them to participate in the new scheme, which has prompted the MHLW to consider further liberalisation of EHC sales.”

Meanwhile, in the UK, following an application from Sanofi, the Medicines & Healthcare products Regulatory Agency last week reclassified Nasacort Allergy Relief (triamcinolone acetonide 55mcg / dose) nasal spray from Pharmacy medicine to General Sales List. The suspension can be used for the relief of symptoms associated with seasonal allergic rhinitis, including sneezing, itchy and runny nose, itchy red or watery eyes, nasal congestion or sinus discomfort in adults aged 18+ years.

In terms of switch drivers, governments seeking to reduce healthcare costs remains a primary factor, but also important is the empowerment of consumers as they increasingly use digital solutions to improve and monitor their health, a trend that is being leveraged into test & treat models. Commenting on the just-published Rx-to-OTC Switch Hot Topic Report, CIMA Senior Market Analyst Victoria Blake said the report “considers the impact of Covid on struggling healthcare systems, and the increased burden on the undertreated population. While traditional mechanisms have proved too slow in recent years, the next generation of switches – such as statins, triptans, oral contraceptives and CBD – require new thinking and a different approach.”

According to Nicholas Hall, “we could be entering a Golden Age. Voltaren Arthritis Pain Relief Gel’s successful US launch; OTC approval for low-dose cannabis in Australia; the possibility of OTC oral contraceptives in a major Western market for the first time; plus recent statements by Sanofi on the likely switches of the antiviral Tamiflu and the erectile dysfunction treatment Cialis. These are just the tonic this industry needs as the recovery from Covid gets underway.”

Our hot topic report Rx-to-OTC Switch is now published! Written by Nicholas Hall’s CIMA team in association with switch expert Joe McGovern of Biograph Inc, you can access information on the historic and current switch environments in key global markets, including an overview of pipeline and strategic considerations. For more information, or to purchase your copy, please contact melissa.lee@NicholasHall.com

Google’s Derm Assist AI tool

Google is making a big move into healthcare with its announcement last week of a new AI skin care tool, Derm Assist, which is set to launch in Europe later this year. The new tool received a Class I medical device CE mark from European regulators, and is backed by landmark research that was published in Nature Medicine this time last year, showing how Google’s AI model was trained on more than 16,000 real-world dermatology cases and achieved accuracy on a par with US board-certified dermatologists. Another more recent study in JAMA Network indicated the AI tool also significantly improved diagnostic accuracy of non-derma specialists such as GPs.

In its blog announcement, Google said: “With our CE marked AI-powered dermatology assist tool, a web-based application that we aim to make available for early testing in the EU later this year, it’s easier to figure out what might be going on with your skin. Simply use your phone’s camera to take three images of the skin, hair or nail concern from different angles. You’ll then be asked questions about your skin type, how long you’ve had the issue and other symptoms that help the AI to narrow down the possibilities. The AI model analyses all of this information and draws from its knowledge of 288 conditions to give you a list of possible conditions that you can then research further. It’s not meant to be a replacement for diagnosis, but rather a good place to start.”

Google said that it sees billions of Google Searches every year related to skin, nail and hair issues, but that it remains difficult for people to describe what they see on their skin through words alone. According to the FT, Google cited studies showing that people only diagnose themselves correctly 13% of the time when it comes to skin conditions, presenting a huge opportunity for the Derm Assist tool. In the blog announcement, Google provided a visual walkthrough of how the tool will work on smartphones, starting with a prompt to submit a picture of your “skin concern” (examples include moles, birthmarks and rashes), with the visual information then analysed by the AI before being converted into a gallery of suggested conditions.

Google is keen to emphasis the inclusivity of its AI model, stating: “To make sure we’re building for everyone, our model accounts for factors like age, sex, race and skin types – from pale skin that does not tan to brown skin that rarely burns. We developed and fine-tuned our model with de-identified data encompassing around 65,000 images and case data of diagnosed skin conditions, millions of curated skin concern images and thousands of examples of healthy skin – all across different demographics.”

Review New Product Activity and the latest digital health developments across the industry with Innovation in CHC 2021, the latest report from CHC New Products Tracker. For more information, or to order your copy, please contact melissa.lee@NicholasHall.com

Vitamin D has a bright future

DSM’s Hologram Sciences has launched its first direct-to-consumer brand, d.velop, an immunity solution with an advanced vitamin D formula, diagnostic kit and digital support. Hologram says d.velop is made with an exclusive form of vitamin D (DSM’s ampli-D) that has been shown to help achieve optimal levels 3x faster and more effectively vs conventional vitamin D supplements. A three-month subscription (US$75 / 180 pills) comes with a free vitamin D test kit containing two tests to measure vitamin D levels before and after taking d.velop. An accompanying free app provides a holistic immunity score, helps consumers track their progress towards a healthier immune system and addresses other potential immunity factors, such as nutrition and sleep. D.velop is also available as a one-time purchase (US$25 / 60 pills) from the brand’s website.

Vitamin D supplements had their season in the sun in 2020, with global sales up 28% to just short of US$2bn, and new product development in the subcategory has reached an all-time high. New delivery formats have been the main source of vitamin D innovation in recent years, so it’s notable that DSM has unveiled a new patented form of the ingredient (ampli-D), marking a real leap forward for the subcategory. DSM has already launched ampli-D as Fortaro tablets in Australia in December 2020, positioned to support the health of bones, eyes, skin and the immune system, while US launch d.velop was awarded 3 stars by Nicholas Hall’s CHC New Products Tracker, not just for its novel formulation but also for the supporting diagnostic test kits and smartphone app.

In other vitamin D news, US VMS industry body CRN (Council for Responsible Nutrition) has launched “Vitamin D & Me!” (vitamindandme.org) – a consumer education initiative on vitamin D and Covid-19. It presents research, expert video interviews and news in a user-friendly format developed by Council for Responsible Nutrition member Nutrasource, focusing on consumers aged 55+ years; older adults are more prone to vitamin D deficiency and are at higher risk from worse outcomes from Covid and other respiratory infections. CRN Foundation President, Steve Mister, commented: “We have been fascinated … at the amount of research being conducted examining the potential relationship between vitamin D and Covid-19. [We are] delivering unbiased education on the latest science, which helps people make smarter decisions to maintain their health.”

Nicholas Hall Writes: “Vitamin D is essential to bone growth and other important bodily functions, and acts synergistically with calcium. The over-use of sunscreens had already given this subcategory stellar growth and Covid has added rocket fuel to what was the sixth fastest-growing subcategory in the global CHC market in 2020. Initiatives like DSM’s are highly appropriate and very welcome, especially as most top CHC players expect to buy-in important developments from technology providers. In the case of vitamin D and the D.velop brand in particular, the latest research from the CRN foundation underlines the significance of this particular innovation in an industry where 94% of all new products launched since 2013 have little or no point of difference.

Now is your final chance to register to join this week’s hot topic webinar focusing on Immunity & Other Drivers for Consumer Healthcare in Asia-Pacific! Join Nicholas to explore the non-existent cough & cold season, e-Commerce, where to find growth and innovation and much more. To register, please contact elizabeth.bernos@NicholasHall.com

European e-Conference report 2021

In this week’s blog, we highlight the key takeaways from our recent European e-Conference and take a closer look at one of the slides from Nicholas Hall’s Global Trends presentation, looking at the fastest-growing brands in consumer healthcare over the past five years.

Nicholas Hall Writes: 100 delegates from around the world joined us in late April for our first-ever e-Conference, and many more are expected to listen to the recording. The conference reviewed global and European trends in the consumer healthcare market, the impact of Covid, changing consumer attitudes and the omnichannel shopper journey, the digital revolution and our forecasts for the future. These and many other topics were covered under the banner of “A Glimpse into the New Normal”.

There is no denying that “immunity” is the biggest buzzword in consumer healthcare at the moment, and has produced some amazing results. We’ve just completed an analysis of the new DB6 data, looking at the fastest-growing brands over the past five years. Just to be clear, this is drawn from the 200 biggest brands and excludes those specifically from China, which are very largely formulated with traditional Chinese medicine. Sambucol, a brand I love dearly and have used for 20 years, shows up as the second fastest growing brand. Only Biofreeze (to be acquired by Reckitt in a deal expected to complete in Q2 2021) has grown faster during this period.

Source: Nicholas Hall’s DB6 database. All values US$mn at MSP.

CHC Insight Europe Editor Sarah Carter and Researcher / Writer Nathalie Corbett filed this report summarising various highlights from our European e-Conference:

  • There is an increased consumer focus on prevention, not just in terms of avoiding Covid-19, but also awareness that people with better overall health have better lifestyle outcomes. Many consumers are no longer looking for treatment, but instead seek to safeguard their future health.
  • During the pandemic, the health consumer has evolved from patient to “consum’actor”, who uses their purchasing power to protect the values and causes they believe in.
  • The consumer is in control of our industry and we need to deliver on their expectations. The best medicine is a consumer who is informed, empowered and inspired.
  • The way consumers shop has been severely disrupted and perhaps irrevocably altered by the pandemic. The CHC industry must respond with agility in order to successfully compete in this omnichannel landscape.
  • Consumers cross these different channels in a way that’s seamless, with lines blurring between communication, point of purchase, advertising, etc.
  • It’s all about the data – get this data culture deeply embedded at all levels of your organisation. It’s also about the right data, and not being inundated with data that isn’t useful. Identify the relevant KPIs and target those.
  • Tech and Big Data can help us gather insights and use these to deliver relevant business developments and product innovations. Consumers themselves are increasingly generating a wealth of data, including via self-monitoring devices.
  • Online can offer opportunities that offline cannot, even when it comes to personal advice. Digital interactions are sometimes preferable vs crowded stores / time constraints.
  • But pharmacies still account for 76% of purchases, and have a superb chance to fight back and regain market share provided they collect new insights into their customers’ shopping journeys.
  • We should no longer refer to e-commerce, but rather e-life. Platforms like Amazon are increasingly media hubs rather than just online stores.
  • Brand building is more important than ever as consumers adapt to the New Normal. We must be present and relevant and focus on creating an emotional bond with the consumer, a traditionally weak area.
  • There can be no return to old strategies and the old way of doing business. It is time for new strategies and New Paradigms.

We hope you enjoyed our European e-Conference 2021! If you couldn’t attend, you can still purchase a recording of the meeting by contacting elizabeth.bernos@NicholasHall.comImmunity & other Growth Drivers will be the focus of our next round of regional hot topic webinars. Starting with a focus on Asia-Pacific on 19 May, on the Americas on 23 June and concluding with Europe on 21 July. Please contact elizabeth.bernos@NicholasHall.com to find out more.

Q1 2021 Results: CCA Round-up

Five of the Top 6 global CHC marketers have now reported their Q1 2021 results, and the clear common theme is a difficult start to the year as a result of the downturn in cough, cold & allergy sales. Global No.1 GSK reported that Consumer Healthcare sales were down 9% as a direct result of the year-on-year “pantry-loading” comparison, including accelerated purchases across all categories driven by the pandemic, combined with a historically weak cold & flu season. GSK’s Respiratory Health portfolio was down 42% in Q1, with Theraflu and Robitussin declining in double-digits, and Contac hit by a high single-digit fall, all adversely impacted by a lower cold & flu season.

Global No.2 J&J reported that Consumer Health worldwide operational sales were down 2.9%, primarily driven by negative prior-year comparisons related to Covid pantry loading in Q1 2020, mainly in OTC products, which declined by 14.8% in Q1 2021 as a result of lower cough, cold & flu incidences. This was partially offset by growth in Listerine mouthwash, Johnson’s baby care products, international skin health / beauty products and Nicorette sales outside the USA.

Sanofi’s Consumer Healthcare sales decreased by 7.3% in Q1 2021, primarily reflecting the weak cough / cold season, as well as a high base for comparison in Q1 2020 and divestments of non-core products. Allergy fell by 6.2%, while Cough & Cold sales were down 59.4% in Q1 2021. This heavy decline was offset by gains for Digestive Wellness (+14.6%), Physical Wellness and Mental Wellness (+18.8%) products. In USA and Rest of the World, growth of the Digestive and Mental Wellness categories partially offset lower Cough / Cold and Pain sales, but in Europe CHC sales fell by 19.3% in Q1.

Reckitt Q1 2021 net revenue was up 4.1% (like-for-like), and e-Commerce was +24%, accounting for 13% of total net revenue, driven by increased investment. Health fell 13.0%, reflecting a volume decline of 14.2% and price / mix improvements of 1.2%, as overall price growth was offset by relatively higher trade investment in North America. The OTC portfolio fell by just under 40%; in addition to challenging comparatives owing to significant pantry-loading in March 2020, this reflects an exceptionally weak cough, cold & flu season – estimated to be around 90% lower than the prior year – resulting in declines for Strepsils, Nurofen and Mucinex.

P&G’s Health Care organic sales were up 3% in Q1 2021, while Personal Health Care organic sales fell by mid-single digits, primarily owing to pandemic-related increases in consumer and retailer inventories in the base period and a weaker than average cough, cold & flu season. Representing 14% of global sales, e-Commerce sales increased by around 50% fiscal year-to-date, with no noticeable change in shopping trends in the quarter. CFO Andre Schulten said in an earnings call that a portion of the impact of commodity cost challenges in the next fiscal year would be offset with price increases in the baby care, feminine care and adult incontinence businesses, which will go into effect in mid-September 2021.

Celine Waller VP, DB6 comments: The poor CHC results reported were set against a robust performance in Q1 2020 when consumers were stockpiling ahead of lockdown restrictions (J&J’s OTC business increased operationally by 25.8% in Q1 2020!) and we expect that they will improve as the year goes on. However, 2021 is expected to be affected by a very weak cough / cold season as lockdowns (still in effect in many markets), social distancing, hygiene measures and mask-wearing continue to suppress incidence of respiratory illnesses, while there are some doubts about whether the high consumption levels of disinfectants and immune-boosting supplements can be sustained. As such, we have lowered our expectations of CHC growth in 2021 to 2.3% in the retail market. However, as highlighted in the P&G results, the 2020 boom in e-Commerce sales is continuing into the current year and we forecast that combined CHC sales in all channels will come out at a respectable 4.0% in 2021.

We are pleased to announce that our annual bestselling report, Nicholas Hall’s CHC Yearbook 2021, is now published digitally! You can analyse key players’ performance, hot topics, global retailing, the Top 15 markets and much more! Print copies will follow soon. For more information, or to order your copy, please contact melissa.lee@NicholasHall.com.

Prebiotics on cusp of exponential growth


According to prebiotics developer, Swiss-based Clasado, the category has “exponential” growth potential, with increasing consumer awareness and an upswing in demand from key players. CEO Per Rehne said: “Because the prebiotics market has gathered pace over a relatively short space of time, it’s easy to forget that the isolated ingredients are still relatively new compared to many of today’s nutrition technologies. Global Market Insights predicts a very solid 8.5% global CAGR until 2024, but it is likely to surpass this … [in a] perfect example of the ‘right technology, connecting with the right market, at the right time’.” He added: “Real market appetite [is] reflected in new product innovation from some of the biggest international brands”.

Clasado is working on a “major project” with P&G, which will see galactooligosaccharide prebiotic ingredient Bimuno  “feature heavily in a novel gummy designed to make a real difference to the consumer.” Rehne concluded: “It’s an exciting time for brand owners and formulators. We’re only just scratching the surface of what prebiotics are capable of in terms of capturing consumer attention and unlocking fundamentally better gut health.”

Coinciding with April’s IBS Awareness Month, i-Health / DSM has launched Culturelle IBS Complete Support in the USA for the dietary management of IBS. The first product from the brand that does not contain probiotics, the medical food – to be used under medical supervision and direction – is powered by HMO (human milk oligosaccharide) bioactive prebiotics, natural digestive nutrients that promote the growth of good gut bacteria. It claims to be able to reduce the severity of symptoms such as stomach pain, bloating, constipation and diarrhoea by 60% and cut days with symptoms by 50%. In tandem, the “Take Back Your Days” campaign offers consumers the chance to win US$100 to spend doing something they enjoy with their reclaimed time. The first 1,000 entrants will receive a box of Culturelle IBS Complete Support, which is available now at a number of retailers with a suggested retail price starting at US$29.98 for a box of 28 single serve packets. The recommended dose for adults and children aged 12+ years is one packet once daily, mixed in liquids or food.

Comment from Dave Redford, Managing Editor, CHC New Products Tracker: This new Culturelle product is a unique proposition in several ways: Formulation (first Culturelle product with no probiotics, just prebiotics); Regulatory status (first Culturelle product to be registered as a medical food); and Positioning (first Culturelle product for IBS). Still by far the No.1 US probiotics & prebiotics brand with sales of over US$150mn, Culturelle has however seen growth slow in the past two years in line with the category overall, as competition intensifies and the market matures. With a claim to offer “more symptom-free days” to IBS sufferers, backed by clinical research, i-Health clearly sees Culturelle IBS Complete Support as offering a new avenue for growth.

Review the best in class innovations among GIs and probiotics & prebiotics from the past year in our recently published Innovation in CHC 2021 report from CHC New Products Tracker. Showcasing 110 of the latest innovations across CHC categories, with a look at trends in delivery format and ingredients, as well as profiling innovation by the leading players, for more information, or to order your copy, please contact melissa.lee@NicholasHall.com

WHO highlights shortage of innovative antibiotics

The world is still failing to develop desperately-needed antibacterial treatments, despite the urgent threat of antibiotic resistance, according to a World Health Organisation report. None of the 43 antibiotics in clinical development sufficiently address drug resistance in the most dangerous bacteria. The majority offer limited clinical benefit over existing treatments, while 82% of recently-approved antibiotics are derivatives of older products with well-established drug-resistance.

WHO highlights 27 non-traditional antibacterial agents, ranging from antibodies to bacteriophages, and therapies that support the patient’s immune response and weaken the bacteria’s effect. However, while there are some promising products in development, only a fraction will make it to the market, owing to economic and scientific challenges. The low return on investment from successful products has limited the interest of major private investors and most large pharma players, and the small to medium-sized companies driving the pipeline often struggle to finance their products through to regulatory approval. 

Source: World Health Organization

Nicholas Hall Writes: “Just when you thought it was safe to go back in the water (to quote the movie “Jaws”), the World Health Organisation reminds us that there could be more and worse to come. The worldwide pharma industry has responded magnificently to Covid, and if a fraction of that effort went into the search for new antibiotics, we could perhaps avoid the next and possibly much worse pandemic, when superbugs attack mankind. I’m not referring to hacking from within the Dark Web, but bacteria for which existing antibiotics will be unable to cope! One medical expert has described this as making Covid look like a vicarage tea party!

To quote WHO: “Opportunities emerging from the Covid-19 pandemic must be seized to bring to the forefront the needs for sustainable investments in R&D of new and effective antibiotics … We need a global sustained effort including mechanisms for pooled funding and new and additional investments to meet the magnitude of the AMR (antimicrobial resistance) threat.” So I hope that Big Pharma will recycle the windfall from Covid vaccines into new antibiotic research, otherwise we will have many more years of lockdown!”

Immunity will be the focus of our next round of regional hot topic webinars, starting with a focus on Asia-Pacific on 19 May, followed by the Americas on 23 June and Europe on 21 July. Please contact elizabeth.bernos@NicholasHall.com to find out more about these upcoming sessions.

CCA down, but mental wellness products boom

Global CHC market sales in bricks & mortar outlets totalled US$150bn in 2020, with growth decelerating to 3.3%. Categories that were hardest hit by the slowdown were concentrated among CCA (notably cough and sore throat remedies) and Dermatologicals (such as lip care, cold sore and head lice treatments), as a result of social distancing guidelines. However, there were some notable sales successes in 2020, including sedatives & sleep aids and herbal memory & brain health supplements.

As we wrote in the latest issue of CHC.NewDirections: “Sleep quality has deteriorated as the Covid-19 pandemic has progressed, according to the ongoing University College London Covid-19 Social Study. Of the more than 70,000 participants, 12.7% reported “very good” sleep quality in March 2020 vs only 7.7% in March 2021. The number of people who said their sleep quality was “very poor” increased from 5.4% (Autumn 2020) to 10.1% at the start of the New Year.”

CIMA Market Analyst, Sacha Hawker, notes that this increase in sleep disturbance has been accompanied by a rise in sleep-related apps and devices in recent years, creating even more crossover between technology and consumer healthcare. And globally, there have been more than 160 new products with a mental wellness positioning since the pandemic began in December 2019 (Source: Nicholas Hall’s CHC New Products Tracker). With lockdown measures still in place alongside other stress factors, we expect this trend to continue.

Four notable 2020 sleep device launches from our Innovation in CHC report:
Withings Analyzer (Europe), SleepCheck (Australia), Sunrise (UK) and CoolDrift Versa (USA)

Commenting on the DB6 results, Nicholas Hall said: So there it is! Finally, the 2020 growth rate was somewhat lower than expected at 5% (all channels of distribution), more or less in line with the five years before the Covid outbreak. But within the market there has been radical change, and the stable overall growth rate cannot disguise the weakness of the cough & cold market – much worse than expected – and indeed of the whole retail sector. At the moment we are working on the short-term and long-term forecasts for the new edition of DB6, and there are puzzled frowns and long faces among the forecasting team.

So where do we look for rays of sunshine? As my colleague Celine Waller writes, anything connected with immunity and disinfection and e-Commerce is having a fine time, and the expectation is that this boom will carry over for two or three more years. And she points to sedatives & sleep aids among the rock stars with a 13% growth rate. This ties in perfectly with earlier predictions made during a webinar given by Jennifer Cooper and I a month ago. If you haven’t listened to the recording of that webinar, I strongly advise you to do so (link here).

Only two weeks to go until our European e-Conference 2021! Register now to explore e-Commerce and other major trends impacting CHC on 28-29 April with Nicholas Hall and a panel of industry experts.
For a look at the full agenda, please click here
To book your place at our European e-Conference, or to find out more about our other webinars, please contact Elizabeth.Bernos@NicholasHall.com